BioCancell Reports Success On Bladder Cancer Study

Israeli cancer treatment developer BioCancell has achieved successful results on 64 percent of patients treated for bladder cancer. The company tested its BC-819 treatment, which is intended for patients that cannot be treated with chemotherapy or Bacillus Calmette-Guerin (BCG). Out of 39 patients treated, cancer was eradicated in 25 and the patients did not develop new tumors over the three-month trial period.